Posted by Michael Wonder on 01 Aug 2016
Combination drugs taking flow-on price deductions for 1 October 2016
1 August 2016 - Combination drugs taking flow-on price reductions for 1 October 2016 have been published.
The 2015 Access and Sustainability amendments to the National Health Act 1953 provide for price disclosure reductions to component drugs to be flowed-on to F2 combination items where this results in a lower price than direct application of price disclosure to the F2 combination item. This type of flow-on reduction to combination drugs on F2 is in addition to the usual flow-on of price reductions to combination drugs on the Combination Drug List (CDL).
The combination drugs in the tables below (both F2 and CDL) are those for which the National Health Act 1953 provides flow-on of component drug reduced prices for the October 2016 price disclosure reduction day. The component drug taking the price disclosure reduction on 1 October 2016 is specified along with an indication of the range within which the proposed ex manufacturer price reduction falls for the combination drug. This information is being provided to give more notice of price reductions, particularly where these are likely to be significant.
